litlas
Log inCreate account

Ignace Vergote

Active 1987–2025

354
Papers
70,017
Citations
133
h-index
343
i10-index

Citations

Citations per year for Ignace Vergote1901: 1 citations1989: 1 citations1990: 2 citations1991: 4 citations1992: 1 citations1994: 2 citations1995: 1 citations1996: 6 citations1997: 5 citations1998: 20 citations1999: 20 citations2000: 37 citations2001: 51 citations2002: 42 citations2003: 88 citations2004: 106 citations2005: 101 citations2006: 105 citations2007: 146 citations2008: 159 citations2009: 204 citations2010: 169 citations2011: 230 citations2012: 318 citations2013: 327 citations2014: 386 citations2015: 385 citations2016: 521 citations2017: 538 citations2018: 471 citations2019: 1,972 citations2020: 2,540 citations2021: 2,753 citations2022: 2,446 citations2023: 2,056 citations2024: 3,341 citations2025: 1,484 citations2026: 43 citations1902–1988: no citations, so these years are not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,208 citing papers, 18.9% of this breakdownChina: 2,440 citing papers, 11% of this breakdownUnited Kingdom: 1,655 citing papers, 7.4% of this breakdownItaly: 1,505 citing papers, 6.8% of this breakdownGermany: 971 citing papers, 4.4% of this breakdownFrance: 934 citing papers, 4.2% of this breakdownCanada: 839 citing papers, 3.8% of this breakdownSpain: 778 citing papers, 3.5% of this breakdownBelgium: 760 citing papers, 3.4% of this breakdownNetherlands: 741 citing papers, 3.3% of this breakdownAustralia: 631 citing papers, 2.8% of this breakdownJapan: 540 citing papers, 2.4% of this breakdown
0%18.9%Other 28.1%

Institutions

Fields

  • Medicine67.2%
  • Biochemistry, Genetics and Molecular Biology24.3%
  • Immunology and Microbiology3.9%
  • Engineering0.9%
  • Computer Science0.9%
  • Materials Science0.7%
  • Other2.1%

Topics

  • Ovarian cancer diagnosis and treatment10.8%
  • Endometrial and Cervical Cancer Treatments6.8%
  • PARP inhibition in cancer therapy6.1%
  • Cancer Immunotherapy and Biomarkers2.3%
  • Intraperitoneal and Appendiceal Malignancies2.1%
  • Endometriosis Research and Treatment2%
  • Other69.9%

Coauthors

All papers

Open in search
  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Authors: Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk - New England Journal of Medicine 2019 cited by 2,262

  2. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    Authors: Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter - New England Journal of Medicine 2019 cited by 2,040

  3. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Authors: Nicole Concin, Xavier Matías‐Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A. Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio González-Martı́n, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A. Nout, D. O’Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke M. Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L. Creutzberg - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2020 cited by 1,933

  4. Epithelial ovarian cancer

    Authors: Stéphanie Lheureux, Charlie Gourley, Ignace Vergote, Amit M. Oza - The Lancet 2019 cited by 1,940

  5. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling

    Authors: Junbin Qian, Siel Olbrecht, Bram Boeckx, Hanne Vos, Damya Laoui, Emre Etlioglu, Els Wauters, Valentina Pomella, Sara Verbandt, Pieter Busschaert, Ayse Bassez, Amelie Franken, Marlies Vanden Bempt, Jieyi Xiong, Birgit Weynand, Yannick Van Herck, Asier Antoranz, Francesca M. Bosisio, Bernard Thienpont, Giuseppe Floris, Ignace Vergote, Ann Smeets, Sabine Tejpar, Diether Lambrechts - Cell Research 2020 cited by 864

  6. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Authors: Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis - New England Journal of Medicine 2016 cited by 2,458

  7. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  8. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Authors: Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Alla Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S. Sonke, Michael J. Birrer, Diane Provencher, Jalid Sehouli, Nicoletta Colombo, Antonio González-Martı́n, Ana Oaknin, Petronella B. Ottevanger, Vilius Rudaitis, Kianoosh Katchar, Huita Wu, Stephen J. O’Keefe, Jane Ruman, Jonathan A. Ledermann - Annals of Oncology 2019 cited by 840

  9. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    Authors: Nicoletta Colombo, Cristiana Sessa, Andreas du Bois, Jonathan A. Ledermann, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Sandro Pignata, Isabelle Ray‐Coquard, Ignace Vergote, Thaïs Baert, I. Belaroussi, A. Dashora, Siel Olbrecht, François Planchamp, Denis Querleu, Thaïs Baert, Susana Banerjee, I. Belaroussi, Paweł Blecharz, Ilan Bruchim, David Cibula, Nicoletta Colombo, Nicole Concin, Ben Davidson, A. Dashora, Mojgan Devouassoux‐Shisheboran, Andreas du Bois, Annamaria Ferrero, Rosalind Glasspool, Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet - Annals of Oncology 2019 cited by 1,165

  10. Survival with Cemiplimab in Recurrent Cervical Cancer

    Authors: Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, Austin Miller, Andreia C. de Melo, Hee-Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy A. Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva M. Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stephanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Jankovic, Chieh-I Chen, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin - New England Journal of Medicine 2022 cited by 427

  11. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    Authors: Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Alexander Reuß, Andrés Poveda, Gunnar B. Kristensen, Roberto Sorio, Ignace Vergote, Petronella O. Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David T. Bollag, Isabelle Ray‐Coquard - Journal of Clinical Oncology 2014 cited by 1,625

  12. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Authors: Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394

  13. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

    Authors: Ignace Vergote, Claes G. Tropé, Frédéric Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, René H.M. Verheijen, Maria E.L. van der Burg, Ángel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Corneel Coens, Leen Verleye, Gavin Stuart, Sërgio Pecorelli, N.S. Reed - New England Journal of Medicine 2010 cited by 2,523

  14. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Authors: I. Ray-Coquard, Alexandra Léary, Sandro Pignata, Claire Cropet, Antonio González-Martı́n, Christian Marth, Shoji Nagao, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Gerhard Bogner, Hiroyuki Yoshida, C. Lefeuvre-Plesse, Paul Buderath, Anna Maria Mosconi, A. Lortholary, Alexander Burges, J. Medioni, Ayşe Balat, Manuel Rodrigues, Tjoung‐Won Park‐Simon, Coraline Dubot, Dominik Denschlag, Benoît You, Éric Pujade-Lauraine, Philipp Harter - Annals of Oncology 2023 cited by 339

  15. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

    Authors: Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, Ana Oaknin, Giovanni Scambia, Domenica Lorusso, Gottfried E. Konecny, Susana Banerjee, Conleth G. Murphy, János L. Tanyi, Hal W. Hirte, Jason Konner, Peter Lim, Monica Prasad-Hayes, Bradley J. Monk, Patricia Pautier, Jiao Wang, Anna Berkenblit, Ignace Vergote, Michael J. Birrer - Annals of Oncology 2021 cited by 292

  16. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula A. Matulonis - New England Journal of Medicine 2012 cited by 1,891

  17. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening

    Authors: Matteo Boretto, Nina Maenhoudt, Xinlong Luo, Aurélie Hennes, Bram Boeckx, Bich Ngoc Bui, Ruben Heremans, Lisa Perneel, Hiroto Kobayashi, Indra Van Zundert, Hilde Brems, Benoit Cox, Marc Ferrante, Hiroshi Uji‐i, Kian Peng Koh, Thomas D’Hooghe, Arne Vanhie, Ignace Vergote, Christel Meuleman, Carla Tomassetti, Diether Lambrechts, Joris Vriens, D. Timmerman, Hugo Vankelecom - Nature Cell Biology 2019 cited by 501

  18. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedländer, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae‐Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth Lowe, Philip Rowe, Ignace Vergote, Éric Pujade-Lauraine, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  19. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Authors: Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J. Carl Barrett, Ursula A. Matulonis - The Lancet Oncology 2014 cited by 1,443

  20. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Authors: Jonathan A. Ledermann, Xavier Matías‐Guiu, Frédéric Amant, Nicole Concin, Ben Davidson, Christina Fotopoulou, Antonio González-Martı́n, Charlie Gourley, Alexandra Léary, Domenica Lorusso, Susana Banerjee, Luis Chiva, David Cibula, Nicoletta Colombo, Sabrina Croce, Ane Gerda Zahl Eriksson, Claire Falandry, D. Fischerová, Philipp Harter, Florence Joly, Conxi Lázaro, C.A.R. Lok, Sven� Mahner, Frederik Marmé, Christian Marth, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Shibani Nicum, Ana Oaknin, José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 cited by 284

  21. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

    Authors: Siel Olbrecht, Pieter Busschaert, Jun Qian, Adriaan Vanderstichele, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, Annick Van den Broeck, An Coosemans, Anne‐Sophie Van Rompuy, Diether Lambrechts, Ignace Vergote - Genome Medicine 2021 cited by 195

  22. Endometrial cancer

    Authors: Frédéric Amant, Philippe Moerman, Patrick Neven, D. Timmerman, Erik Van Limbergen, Ignace Vergote - The Lancet 2005 cited by 1,517

  23. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Authors: Philipp Harter, Jalid Sehouli, Domenica Lorusso, Alexander Reuß, Ignace Vergote, Christian Marth, Jae‐Weon Kim, Francesco Raspagliesi, Björn Lampe, Giovanni Aletti, Werner Meier, David Cibula, Alexander Mustea, Sven� Mahner, Ingo B. Runnebaum, Barbara Schmalfeldt, Alexander Burges, Rainer Kimmig, Giovanni Scambia, Stefano Greggi, Felix Hilpert, Annette Hasenburg, Peter Hillemanns, Giorgio Giorda, Ingo von Leffern, Carmen Schade‐Brittinger, Uwe Wagner, Andreas du Bois - New England Journal of Medicine 2019 cited by 600

  24. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    Authors: Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, Jung‐Yun Lee, Susana Banerjee, Fernando Cotait Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen, Luís Manso, Linn Woelber, Anneke M. Westermann, Allan Covens, Kosei Hasegawa, Byoung‐Gie Kim, Miriam Raimondo, Maria Bjurberg, Felipe Melo Cruz, Antoine Angelergues, David Cibula, Lisa Barraclough, Ana Oaknin, Christine Gennigens, L. Nicacio, Melinda Siew Leng Teng, Elizabeth Whalley, Ibrahima Soumaoro, Brian M. Slomovitz - New England Journal of Medicine 2024 cited by 159